Therapeutic potential of targeting the FLNA-regulated Wee1 kinase in adrenocortical carcinomas

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Filamin A (FLNA) is underexpressed in adrenocortical carcinomas (ACC), correlating with less aggressive tumor behavior.
• FLNA deficiency may lead to increased Wee1 kinase, a cell cycle regulator implicated in various cancers.
• Understanding FLNA's role in Wee1 regulation is crucial for developing targeted ACC therapies.

Purpose of the Study:

• To investigate the relationship between FLNA expression and Wee1 kinase in ACC.
• To evaluate the efficacy of the Wee1 inhibitor AZD1775 in ACC models.
• To determine how FLNA influences AZD1775's effectiveness in ACC.

Main Methods:

• Analysis of FLNA and Wee1 protein levels in ACC tissues and cell lines.
• FLNA knockdown and overexpression experiments to assess effects on Wee1, p-CDK1, and cyclin B1.
• Treatment of ACC cells with Wee1 inhibitor AZD1775 and assessment of proliferation, viability, and apoptosis.
• Evaluation of FLNA's impact on AZD1775 efficacy.

Main Results:

• ACC tissues exhibit reduced FLNA and elevated Wee1 compared to normal adrenal glands.
• FLNA knockdown increases Wee1 protein levels, while FLNA overexpression decreases them.
• FLNA promotes Wee1 degradation, evidenced by increased p-Wee1 (Ser123) upon FLNA transfection.
• AZD1775 effectively reduces ACC cell proliferation and viability, inducing cell death.
• FLNA depletion enhances AZD1775's anti-proliferative and pro-apoptotic effects in ACC.

Conclusions:

• FLNA negatively regulates Wee1 expression in ACC by promoting its degradation.
• Low FLNA levels in ACC contribute to increased Wee1, driving cancer cell proliferation.
• Wee1 inhibition represents a promising therapeutic strategy for ACC, particularly in FLNA-deficient tumors.